These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 3778825)

  • 1. The haemorrhagic and antithrombotic effects of dermatan sulphate.
    Fernandez F; Van Ryn J; Ofosu FA; Hirsh J; Buchanan MR
    Br J Haematol; 1986 Oct; 64(2):309-17. PubMed ID: 3778825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model.
    Maggi A; Abbadini M; Pagella PG; Borowska A; Pangrazzi J; Donati MB
    Haemostasis; 1987; 17(6):329-35. PubMed ID: 3428718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.
    Buchanan MR; Boneu B; Ofosu F; Hirsh J
    Blood; 1985 Jan; 65(1):198-201. PubMed ID: 3965047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
    Hoppensteadt D; Walenga JM; Fareed J
    Thromb Res; 1990 Nov; 60(3):191-200. PubMed ID: 2084948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo.
    Van Ryn-McKenna J; Ofosu FA; Gray E; Hirsh J; Buchanan MR
    Ann N Y Acad Sci; 1989; 556():304-12. PubMed ID: 2735661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
    Ofosu FA; Modi GJ; Blajchman MA; Buchanan MR; Johnson EA
    Biochem J; 1987 Dec; 248(3):889-96. PubMed ID: 2963622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
    Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB
    Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation.
    Van Ryn-McKenna J; Ofosu FA; Hirsh J; Buchanan MR
    Br J Haematol; 1989 Feb; 71(2):265-9. PubMed ID: 2522314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs.
    Thomas DP; Merton RE; Barrowcliffe TW
    Ann N Y Acad Sci; 1989; 556():313-22. PubMed ID: 2735662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit.
    Carrie D; Caranobe C; Gabaig AM; Larroche M; Boneu B
    Thromb Haemost; 1992 Dec; 68(6):637-41. PubMed ID: 1287877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice.
    Brister SJ; Ofosu FA; Heigenhauser GJ; Gianese F; Buchanan MR
    Thromb Haemost; 1994 Apr; 71(4):468-73. PubMed ID: 8052965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
    Merton RE; Thomas DP
    Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low affinity heparin is an antithrombotic agent.
    Gray E; Cesmeli S; Lormeau JC; Davies AB; Lane DA
    Thromb Haemost; 1994 Feb; 71(2):203-7. PubMed ID: 8191399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.
    Hoppensteadt D; Racanelli A; Walenga JM; Fareed J
    Semin Thromb Hemost; 1989 Oct; 15(4):378-85. PubMed ID: 2530633
    [No Abstract]   [Full Text] [Related]  

  • 16. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not.
    Cadroy Y; Dol F; Caranobe C; Petitou M; Lormeau JC; Sié P; Choay J; Boneu B
    Thromb Haemost; 1988 Apr; 59(2):295-8. PubMed ID: 2838927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin.
    Thomas DP; Gray E; Merton RE
    Thromb Haemost; 1990 Oct; 64(2):290-3. PubMed ID: 2270536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation.
    Cade JF; Buchanan MR; Boneu B; Ockelford P; Cater CJ; Cerskus AL; Hirsh J
    Thromb Res; 1984 Sep; 35(6):613-25. PubMed ID: 6506020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J; Ofosu F; Buchanan M
    Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.